carbidopa/entacapone/levodopa (Stalevo)
Jump to navigation
Jump to search
Introduction
Tradename: Stalevo Contains carbidopa/levodopa & entacapone.
Indications
- Parkinson's disease
- for those patients already taking Sinemet plus entacapone
- for those patients wearing off Sinemet
Dosage
- one tablet/dose; maximum 8 tablets/day
Tabs: 3 strengths of carbidopa/levodopa
- 12.5/50, 25/100 37.5/150 (mg/mg)
- 200 mg of entacapone
Adverse effects
- see Sinemet & entacapone
- most common
- prostate cancer ?[3]
- increased cardiovascular risk relative to Sinemet[4]
- no risk in risk of cardiovascular events[5]
More general terms
Components
- carbidopa (Lodosyn)
- levodopa; L-3-hydroxytyrosine; L-3,4-dihydroxyphenylalanine; L-dopa (Dopar, Larodopa, Inbrija)
- entacapone (Comtan)
References
- ↑ Prescriber's Letter 10(8):45 2003
- ↑ Bronstein J, In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 29-Oct 2, 2004
- ↑ 3.0 3.1 FDA Medwatch Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm206934.htm
- ↑ 4.0 4.1 FDA Medwatch Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm223423.htm
- ↑ 5.0 5.1 4) FDA Safety Alert. Oct 26, 2015 Entacapone: Drug Safety Communication - FDA Review Found No Increased Cardiovascular Risks. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm469162.htm